Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Posted: Tuesday, June 30, 2020

Suresh S. Ramalingam, MD, of Emory University, talks about how the CheckMate 227 trial could alter first-line treatment for patients with advanced non–small cell lung cancer, in light of its 3-year overall survival data favoring nivolumab plus ipilimumab over chemotherapy.